Annika Rose Bergstrom

Dr. Annika Rose Bergstrom

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
HWHope D. Welhaven
Hope D. Welhaven
AWAvery H. Welfley
Avery H. Welfley
PBPriyanka Brahmachary
Priyanka Brahmachary
ABAnnika Rose Bergstrom
Annika Rose Bergstrom
EHEden Houske
Eden Houske
RJRonald K June
Ronald K June
Osteoarthritis (OA) is a chronic joint disease with heterogenous metabolic pathology. To gain insight into OA-related metabolism, metabolite extracts from healthy (n = 11) and end-stage osteoarthritic cartilage (n = 35) were analyzed using liquid chromatography–mass spectrometry metabolomic profiling. Specific metabolites and metabolic pathways, including lipid and amino acid pathways, were differentially regulated in osteoarthritis-derived and healthy cartilage. The detected alterations in amino acids and lipids highlighted key differences in bioenergetic resources, matrix homeostasis, and mitochondrial alterations in OA-derived cartilage compared to healthy cartilage. Moreover, the metabolomic profiles of osteoarthritic cartilage separated into four distinct endotypes, highlighting the heterogenous nature of OA metabolism and the diverse landscape within the joint in patients. The results of this study demonstrate that human cartilage has distinct metabolomic profiles in healthy and end-stage OA patients. By taking a comprehensive approach to assess metabolic differences between healthy and osteoarthritic cartilage and within osteoarthritic cartilage alone, several metabolic pathways with distinct regulation patterns were detected. Additional investigation may lead to the identification of metabolites that may serve as valuable indicators of disease status or potential therapeutic targets.

12 August 2024 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Open access
EKElizabeth R. Kahle
Elizabeth R. Kahle
HFHooman Fallahi
Hooman Fallahi
ABAnnika Rose Bergstrom
Annika Rose Bergstrom
ALAnita Li
Anita Li
CTColette E. Trouillot
Colette E. Trouillot
MMMichele S. Marcolongo
Michele S. Marcolongo
In osteoarthritis (OA), degradation of cartilage pericellular matrix (PCM), the proteoglycan-rich immediate cell microniche, is a leading event of disease initiation. This study demonstrated that biomimetic proteoglycans (BPGs) can diffuse into human cartilage from both normal and osteoarthritic donors and are preferentially localized within the PCM. Applying immunofluorescence (IF)-guided AFM nanomechanical mapping, we show that this localization of BPGs increases the PCM micromodulus of both normal and OA specimens. These results illustrate the capability of BPGs to integrate with degenerative tissues and support the translational potential of BPGs for treating human OA and other diseases associated with proteoglycan degradation.

1 June 2023 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
EHEden A. Houske
Eden A. Houske
MGMatthew Glimm
Matthew Glimm
ABAnnika Rose Bergstrom
Annika Rose Bergstrom
SSSally K. Slipher
Sally K. Slipher
HWHope D. Welhaven
Hope D. Welhaven
AHAlyssa K. Hahn
Alyssa K. Hahn
To our knowledge, this study is the first to generate urinary global metabolomic profiles from individuals with early-stage ADPKD with preserved renal function for biomarker discovery. The exploratory dataset reveals metabolic pathway alterations that may be responsible for early cystogenesis and rapid disease progression and may be potential therapeutic targets and pathway sources for candidate biomarkers. From these results, we generated a panel of candidate diagnostic and prognostic biomarkers of early-stage ADPKD for future validation.

25 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HWHope D. Welhaven
Hope D. Welhaven
AWAvery H. Welfley
Avery H. Welfley
PBPriyanka Brahmachary
Priyanka Brahmachary
ABAnnika Rose Bergstrom
Annika Rose Bergstrom
EHEden Houske
Eden Houske
RJRonald K June
Ronald K June
Objective Osteoarthritis (OA) is a chronic joint disease with heterogenous metabolic pathology. To gain insight into OA-related metabolism, healthy and end-stage osteoarthritic cartilage were compared metabolically to uncover disease-associated profiles, classify OA-specific metabolic endotypes, and identify targets for intervention for the diverse populations of individuals affected by OA. Design Femoral head cartilage (n=35) from osteoarthritis patients were collected post-total joint arthroplasty. Healthy cartilage (n=11) was obtained from a tissue bank. Metabolites from all cartilage samples were extracted and analyzed using liquid chromatography-mass spectrometry metabolomic profiling. Additionally, cartilage extracts were pooled and underwent fragmentation analysis for biochemical identification of metabolites. Results Specific metabolites and metabolic pathways, including lipid- and amino acid pathways, were differentially regulated between osteoarthritis-derived and healthy cartilage. The detected alterations of amino acids and lipids highlight key differences in bioenergetic resources, matrix homeostasis, and mitochondrial alterations in osteoarthritis-derived cartilage compared to healthy. Moreover, metabolomic profiles of osteoarthritic cartilage separated into four distinct endotypes highlighting the heterogenous nature of OA metabolism and diverse landscape within the joint between patients. Conclusions The results of this study demonstrate that human cartilage has distinct metabolomic profiles between healthy and end-stage osteoarthritis patients. By taking a comprehensive approach to assess metabolic differences between healthy and osteoarthritic cartilage, and within osteoarthritic cartilage alone, several metabolic pathways with distinct regulation patterns were detected. Additional investigation may lead to the identification of metabolites that may serve as valuable indicators of disease status or potential therapeutic targets.

8 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
EHEden A. Houske
Eden A. Houske
MGMatthew G. Glimm
Matthew G. Glimm
ABAnnika Rose Bergstrom
Annika Rose Bergstrom
SSSally K. Slipher
Sally K. Slipher
HWHope D. Welhaven
Hope D. Welhaven
AHAlyssa K. Hahn
Alyssa K. Hahn
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the formation of numerous fluid-filled cysts that lead to progressive loss of functional nephrons. Currently, there is an unmet need for diagnostic and prognostic indicators of early stages of the disease. Metabolites were extracted from the urine of early-stage ADPKD patients (n=48) and age- and sex-matched normal controls (n=47) and analyzed by liquid chromatography-mass spectrometry. Orthogonal partial least squares-discriminant analysis was employed to generate a global metabolomic profile of early ADPKD for the identification of metabolic pathway alterations and discriminatory metabolites as candidates of diagnostic and prognostic biomarkers. The global metabolomic profile exhibited alterations in steroid hormone biosynthesis and metabolism, fatty acid metabolism, pyruvate metabolism, amino acid metabolism, and the urea cycle. A panel of 46 metabolite features were identified as candidate diagnostic biomarkers. Notable putative identities of candidate diagnostic biomarkers for early detection include creatinine, cAMP, dCMP, various androgens (testosterone, 5alpha-androstane-3,17,dione, trans-dehydroandrosterone), betaine aldehyde, phosphoric acid, choline, 18-hydroxycorticosterone, and cortisol. Metabolic pathways associated with variable rates of disease progression included steroid hormone biosynthesis and metabolism, vitamin D3 metabolism, fatty acid metabolism, the pentose phosphate pathway, tricarboxylic acid cycle, amino acid metabolism, sialic acid metabolism, and chondroitin sulfate and heparin sulfate degradation. A panel of 41 metabolite features were identified as candidate prognostic biomarkers. Notable putative identities of candidate prognostic biomarkers include ethanolamine, C20:4 anandamide phosphate, progesterone, various androgens (5alpha-dihydrotestosterone, androsterone, etiocholanolone, epiandrosterone), betaine aldehyde, inflammatory lipids (eicosapentaenoic acid, linoleic acid, stearolic acid), and choline. Our exploratory data support metabolic reprogramming in early ADPKD and demonstrate the ability of liquid chromatography-mass spectrometry-based global metabolomic profiling to detect metabolic pathway alterations as new therapeutic targets and biomarkers for early diagnosis and tracking disease progression of ADPKD.

15 December 2025 in Regenerative Engineering and Translational Medicine
Verified
Journal Article
Open access
PDF file
ABAnnika Rose Bergstrom
Annika Rose Bergstrom
ALAnita Li
Anita Li
LHLin Han
Lin Han
MMMichele S. Marcolongo
Michele S. Marcolongo
Proteoglycans are ubiquitous and physiologically active components of the extracellular matrix. The atomic, molecular, and macromolecular chemical structure and organization of proteoglycans contribute to the biological activity and biophysical functioning within the extracellular matrix. Disruption in proteoglycan biosynthesis, caused by genetic mutations or cell phenotype, can lead to disease and aberrant pathology. Structural alterations to proteoglycans have also been implicated in disease and pathology. The structure, processing, and function of proteoglycans are intertwined. Deviations from homeostasis can profoundly affect biological functioning. To address these issues and better understand proteoglycan behavior, scientists have sought to recapitulate proteoglycan components and the molecular and macromolecular structure/property relationships in proteoglycans. To accomplish this, researchers have designed biological mimics for native proteoglycans, termed proteoglycan mimics and biomimetic proteoglycans. In this review, we examine the materials design behind proteoglycan mimics, showcasing their applications in different tissue types for molecular engineering. Additionally, we showcase the use of proteoglycan mimics to study the interaction between the designed material and the biology it interacts with, termed the biological interface. Lastly, we discuss how understanding the biological interface has led to research on the implementation of biomimetic proteoglycans for tissue regeneration with the potential to be used as a regenerative medicine. This review aims to honor Nicholas A. Peppas for his landmark contributions to the field of regenerative engineering and functional biomaterials. Lay Summary: Proteoglycans are macromolecules containing a protein core with one or more sugar side chains, called glycosaminoglycans. Proteoglycans are important for the structure and maintenance of healthy tissue. As proteoglycans degrade, tissue becomes unhealthy, causing disorder and disease. To fix this, researchers have designed biological mimics for proteoglycans. Since proteoglycans are common throughout the body, the applications of proteoglycan mimics for molecular engineering are endless. This work discusses the importance of designing biological mimics to native proteoglycans found within the human body.